RxDoctor Payments DataLook up a doctor →

Austina Cho, MD

Psychiatry · Buena Park, CANPI 1780770453

Payments from drug & device makers

$8,852,056in general payments, 2019–2025

Across 1,078 payments — averaging $8211.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3.1M
  • Sage Therapeutics, LLC$2.1M
  • Boehringer Ingelheim$566K
  • Biogen$401K
  • Sumitomo Pharma America, Inc.$391K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$360K
  • plus $1.9M from 27 others
$51,771in research payments, 2019–2025

Across 9 payments — averaging $5752.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$38K
  • Pfizer$13K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)393$3,142,150
Sage Therapeutics, LLC68$2,110,088
Boehringer Ingelheim14$565,863
Biogen4$401,314
Sumitomo Pharma America, Inc.174$390,851
Otsuka Pharmaceutical Development & Commercialization, Inc.15$360,248
Teva Pharmaceuticals USA, Inc.15$302,308
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)84$268,769
Vivus LLC12$186,118
Supernus Pharmaceuticals, Inc.11$158,915
H. Lundbeck A S12$149,897
Regeneron21$125,797
Biohaven Pharmaceutical Holding Company Ltd.33$123,444
Biohaven Pharmaceuticals, Inc.14$96,340
Takeda Pharmaceuticals U.S.A., Inc.31$92,009
Pfizer17$83,508
Janssen Research & Development, LLC8$83,122
Eli Lilly6$64,121
Alkermes, Inc.41$61,582
Neurocrine Biosciences, Inc.29$31,800
Avanir Pharmaceuticals, Inc.8$13,300
Boehringer Ingelheim RCV GmbH & Co KG17$11,374
Bristol Myers Squibb1$10,450
Amneal Pharmaceuticals LLC2$8,867
Currax Pharmaceuticals LLC3$6,811
E.r. Squibb & Sons, L.L.C.5$1,860
Sunovion Pharmaceuticals Inc.16$451
Johnson & Johnson7$332
Indivior Inc.8$196
Otsuka America Pharmaceutical, Inc.5$86
Lundbeck LLC2$40
Ironshore Pharmaceuticals Inc.1$25
Luye Pharma (USA) Ltd.1$22

How this compares

$8,852,056 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Medicare billing

Part B allowed, 2024
$45,422
Medicare patients
88
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Buena Park

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →